ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor
about
Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumoursExpression of ADAM15 in rheumatoid synovium: up-regulation by vascular endothelial growth factor and possible implications for angiogenesisADAM28 is overexpressed in human non-small cell lung carcinomas and correlates with cell proliferation and lymph node metastasisStructural and functional impact of cancer-related missense somatic mutations.ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis.Gamma-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptorTherapeutic strategies for inhibiting invasion in glioblastoma.ADAM12 and ADAM17 gene expression in laser-capture microdissected and non-microdissected breast tumors.The role of SnoN in transforming growth factor beta1-induced expression of metalloprotease-disintegrin ADAM12.Copy number variation detection in whole-genome sequencing data using the Bayesian information criterion.Cell cholesterol modulates metalloproteinase-dependent shedding of low-density lipoprotein receptor-related protein-1 (LRP-1) and clearance function.Z-DNA-forming silencer in the first exon regulates human ADAM-12 gene expression.N-glycosylation regulates ADAM8 processing and activationMetzincin proteases and their inhibitors: foes or friends in nervous system physiology?Role of A disintegrin and metalloprotease-12 in neutrophil recruitment induced by airway epithelium.Alternative mRNA splicing generates two distinct ADAM12 prodomain variants.ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasisADAM12 produced by tumor cells rather than stromal cells accelerates breast tumor progression.Expression of a-disintegrin and metalloproteinase 10 correlates with grade of malignancy in human glioma.The Disintegrin and Metalloprotease ADAM12 Is Associated with TGF-β-Induced Epithelial to Mesenchymal Transition.ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasionADAM12 induces estrogen-independence in breast cancer cells.The role of proteases in regulating Eph/ephrin signaling.ADAM proteases, ErbB pathways and cancer.Tissue fibrosis and carcinogenesis: divergent or successive pathways dictate multiple molecular therapeutic targets for oligo decoy therapies.(Make) stick and cut loose--disintegrin metalloproteases in development and disease.ADAMs, cell migration and cancer.miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal.Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia.Inhibition of angiogenesis and invasion in malignant gliomas.Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein.ADAM9 Expression Is Associate with Glioma Tumor Grade and Histological Type, and Acts as a Prognostic Factor in Lower-Grade GliomasDifferential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells.The EGFR-HER2 module: a stem cell approach to understanding a prime target and driver of solid tumors.Metalloproteinases ADAM12 and MMP-14 are associated with cavernous sinus invasion in pituitary adenomas.Upregulation of ADAM12 contributes to accelerated cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) in Non-Hodgkin's Lymphoma.ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma.
P2860
Q24651722-AA8833AA-46B1-4C65-8F1B-72D9DD0AA784Q24812644-70F78CC8-2A0E-4D36-B730-C42FCE4008F0Q28264390-2EF575F7-8B33-4EA5-8DBC-339E54D456EFQ30404960-41E4B4FF-80AA-48D6-8292-24BA77C90C6EQ31148772-3F7E4331-B4C6-48D9-B010-902309CF6B30Q33351256-60715580-D385-4167-A55F-A8693D8598DAQ33391513-51EC88DD-8EBE-4C06-AAB5-AD21D38F5A9BQ33426563-F07E1C02-4F1F-4C8B-82CD-396084AB9632Q33794994-65DDF9A5-1972-4386-A6F1-76EB4976034EQ33991229-07EDDC58-D6BA-4453-AFF9-009AB4044F6CQ34069542-81F6F32C-EBD3-4574-8226-CFB9FAE1CD7BQ34180389-D8BBE177-8EA0-4BEF-8546-2C518A169405Q34471968-1F2AF70D-68D6-426A-A1FF-3920A6B9E851Q34580432-76FB5248-9DBB-491F-85BC-B343F7EAC5E5Q34768858-881A2B8B-BED1-404B-8BA6-F2671EB683A4Q34943914-48F8163E-2B04-4B9D-BC2E-C0E03695926BQ35014541-93908879-F1D5-421D-B2FF-C33DEC4D17E4Q35063483-00892BF8-688B-40DF-A6F8-147EEB92128EQ35560725-7F0E540C-B00F-4955-91BB-43055FAB676EQ35742031-61D740F6-5E21-4B54-89B8-CC9DD395E8CCQ35788620-48AF2FEA-801A-42C6-9BB7-D47BD68AD54AQ35815285-843EB7A5-C883-4A3B-84C2-73C78A61DF23Q35827939-BCDA097A-5D2D-48B5-8BFD-00AECC6648E0Q36054273-8CE5B524-C714-4917-8E8C-5C88E92BF024Q36125009-CA867D6E-B341-4BF0-9644-F45C93E6B184Q36187030-4914962D-EA88-472E-B8D2-F28A6E6AD74BQ36366580-CE19A7CE-33D2-4AF3-92A4-14F6250FAAF2Q36452759-729192FE-9699-4D66-AFFC-745F525E9868Q36471116-00BFA5E3-154B-489E-A0FF-A164808310BBQ36545707-AA00F179-E9B8-47C2-A202-11A5C2336348Q36772590-7D6CF95C-15C2-4D27-9BA5-CC4A7F3D6148Q37004664-F879F59A-53C3-4EE8-99B3-B09993251D86Q37085961-099E219D-3E97-43E7-9C8E-391F2CC946B7Q37286187-8B49DFDC-6435-4424-A7DE-0B6E5A83FBB0Q37299495-1E32AB74-AE5D-45AD-BFCA-D3FFF4406215Q37653216-0B91C8B8-23A7-4E4C-84BF-4B5D5CA4D124Q38598710-29D17773-FBA0-4B0E-BFF4-92353D45ABC1Q38773281-FCFEB950-8B60-4831-992E-A74CEA04B20CQ38843959-781625D5-2147-47E3-8E13-78F09AC95637Q38880697-11D03A21-E053-4FE8-B492-7151E4095679
P2860
ADAM12 is selectively overexpressed in human glioblastomas and is associated with glioblastoma cell proliferation and shedding of heparin-binding epidermal growth factor
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@ast
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@en
type
label
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@ast
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@en
prefLabel
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@ast
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@en
P2093
P2860
P1476
ADAM12 is selectively overexpr ...... inding epidermal growth factor
@en
P2093
Aiko Okada
Eiji Ikeda
Eiko Ohuchi
Kazunari Yoshida
Masayuki Shimoda
Mitsutoshi Nakada
Takahide Kodama
Takashi Ohtsuka
Takayuki Shiomi
Yasunori Okada
P2860
P304
P356
10.1016/S0002-9440(10)63429-3
P407
P577
2004-11-01T00:00:00Z